| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ... New England Journal of Medicine 372 (4), 311-319, 2015 | 3901 | 2015 |
| Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study Journal Clinical Oncology, 2016 | 1045 | 2016 |
| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 523 | 2018 |
| Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma RW Merryman, HT Kim, PL Zinzani, C Carlo-Stella, SM Ansell, ... Blood, The Journal of the American Society of Hematology 129 (10), 1380-1388, 2017 | 253 | 2017 |
| Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Blood, The Journal of the American Society of Hematology 124 (21), 291-291, 2014 | 201 | 2014 |
| A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma E Racila, BK Link, WK Weng, TE Witzig, S Ansell, MJ Maurer, J Huang, ... Clinical Cancer Research 14 (20), 6697-6703, 2008 | 192 | 2008 |
| Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib J Jones, MY Choi, AR Mato, RR Furman, MS Davids, LT Heffner, ... Blood 128 (22), 637, 2016 | 83 | 2016 |
| NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020: featured updates to the NCCN guidelines N Mehta-Shah, SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, ... Journal of the National Comprehensive Cancer Network 18 (5), 522-536, 2020 | 81 | 2020 |
| T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, J Brammer, ... Journal of the National Comprehensive Cancer Network 20 (3), 285-308, 2022 | 64 | 2022 |
| NCCN guidelines insights: T-cell lymphomas, version 2.2018 SM Horwitz, SM Ansell, WZ Ai, J Barnes, SK Barta, M Choi, MW Clemens, ... Journal of the National Comprehensive Cancer Network 16 (2), 123-135, 2018 | 58 | 2018 |
| Preliminary results of a phase 1 trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL C Querfeld, T Pacheco, FM Foss, AS Halwani, P Porcu, AG Seto, ... blood 128 (22), 1829, 2016 | 53 | 2016 |
| Proposed algorithm for managing ibrutinib-related atrial fibrillation A Vrontikis, J Carey, JA Gilreath, A Halwani, DM Stephens, ... Oncology 30 (11), 970-978, 2016 | 41 | 2016 |
| NCCN guidelines insights: T-cell lymphomas, version 1.2021: Featured updates to the NCCN guidelines SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, MW Clemens, A Dogan, ... Journal of the National Comprehensive Cancer Network 18 (11), 1460-1467, 2020 | 40 | 2020 |
| Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients C Querfeld, FM Foss, LC Pinter-Brown, P Porcu, BM William, T Pacheco, ... Blood 130, 820, 2017 | 29 | 2017 |
| Nivolumab in patients with relapsed or refractory hodgkin lymphoma-preliminary safety, efficacy and biomarker results of a phase i study P Armand, SM Ansell, AM Lesokhin, A Halwani, MM Millenson, ... Blood 124 (21), 289, 2014 | 28 | 2014 |
| Phase 1 trial of cobomarsen, an inhibitor of Mir-155, in cutaneous T cell lymphoma C Querfeld, FM Foss, YH Kim, L Pinter-Brown, BM William, P Porcu, ... Blood 132, 2903, 2018 | 27 | 2018 |
| Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells SS Han, VS Tompkins, DJ Son, NL Kamberos, LL Stunz, A Halwani, ... Biochemical and biophysical research communications 436 (4), 660-665, 2013 | 26 | 2013 |
| Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma … YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... Blood 130, 817, 2017 | 25 | 2017 |
| Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. JA Jones, WG Wierda, MY Choi, MS Davids, BD Cheson, RR Furman, ... Journal of Clinical Oncology 34 (15_suppl), 7519-7519, 2016 | 24 | 2016 |
| Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with nivolumab for relapsed/refractory Hodgkin lymphoma P Armand, PL Zinzani, GP Collins, JB Cohen, AS Halwani, C Carlo-Stella, ... Blood 128 (22), 3502, 2016 | 23 | 2016 |
Brian C. SauerUniversity of UtahПідтверджена електронна адреса в utah.edu
